PTGX
Protagonist Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+31/100
Last price
140.00
▼ 0.63 (0.45%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
142.00
Prev close
140.63
Day high
141.00
Day low
136.09
Volume
635.71K
Market cap
$8.97B
P/E (TTM)
135.97
52W range
64.50 – 160.81
Day trading desk
Gap from prior close
+0.97%
Prior close 140.63
VWAP
138.53
+1.06% from price
Relative volume
1.67×
Unusually busy
Session range
6.74%
133.50 – 142.50
Position in range
72%
Near session high
ATR (14D)
4.71
3.37% of price
Prior day high
142.51
PDH
Prior day low
138.08
PDL
Bid / ask spread
—
Quote not published
Session volume
1.06M
Avg 632.66K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.62%
-3.6%
1M
-4.82%
-6.0%
3M
-0.99%
-5.5%
6M
+33.68%
+15.5%
YTD
+58.79%
+44.5%
1Y
+113.93%
+97.5%
3Y
+731.47%
+649.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PTGX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-22.91K
Net selling
Buy transactions
10
439.97K shares
Sell transactions
9
462.88K shares
Net transactions
+19
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
458.78K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | PATEL DINESH V Chief Executive Officer |
CONVERSION | 125.00K | $2.70M | Direct |
| Sep 10, 26 | PATEL DINESH V Chief Executive Officer |
SELL | 125.00K | $18.24M | Direct |
| Sep 3, 26 | PATEL DINESH V Chief Executive Officer |
STOCK | 510 | $0 | Direct |
| Aug 11, 26 | PATEL DINESH V Chief Executive Officer |
CONVERSION | 100.00K | $2.16M | Direct |
| Aug 11, 26 | PATEL DINESH V Chief Executive Officer |
SELL | 100.00K | $14.89M | Direct |
| Jun 23, 26 | WADDILL WILLIAM D Director |
CONVERSION | 9.00K | $148.86K | Direct |
| Jun 23, 26 | WADDILL WILLIAM D Director |
SELL | 9.00K | $1.06M | Direct |
| Jun 10, 26 | WADDILL WILLIAM D Director |
CONVERSION | 9.00K | $134.64K | Direct |
| Jun 10, 26 | WADDILL WILLIAM D Director |
SELL | 9.00K | $969.12K | Direct |
| May 29, 26 | WADDILL WILLIAM D Director |
CONVERSION | 9.00K | $106.20K | Direct |
| May 29, 26 | WADDILL WILLIAM D Director |
SELL | 9.00K | $896.76K | Direct |
| May 12, 26 | PATEL DINESH V Chief Executive Officer |
CONVERSION | 75.00K | $1.62M | Direct |
| May 12, 26 | PATEL DINESH V Chief Executive Officer |
CONVERSION | 75.00K | $1.62M | Direct |
| May 12, 26 | PATEL DINESH V Chief Executive Officer |
SELL | 75.00K | $7.51M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALI ASIF |
Chief Financial Officer | 59.00K | Sale |
GIRAUDO BRYAN M. |
Director | — | Sale |
GUPTA SUNEEL |
Officer | 267.43K | Conversion of Exercise of derivative security |
MOLINA ARTURO MD |
Officer | 84.11K | Conversion of Exercise of derivative security |
O DOWD SARAH A |
Director | 7.83K | Stock Award(Grant) |
PATEL DINESH V |
Chief Executive Officer | 522.97K | Conversion of Exercise of derivative security |
SELICK HAROLD E |
Director | 60.84K | Conversion of Exercise of derivative security |
WADDILL WILLIAM D |
Director | 7.83K | Conversion of Exercise of derivative security |
WILLIAMS LEWIS T |
Director | 7.83K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$8.97B
Enterprise value$8.20B
Revenue (TTM)$281.99M
Gross profit$281.99M
EBITDA$59.88M
Net income$82.91M
EPS (TTM)$1.02
Free cash flow$96.15M
Total cash$782.58M
Total debt$9.22M
Book value / share$13.01
Shares outstanding64.71M
Float52.89M
Short % of float14.62%
Dividend yield0.00%
Beta (5Y)1.52
Valuation & profitability ratios
Trailing P/E135.97
Forward P/E-696.41
PEG ratio—
Price / sales—
Price / book10.66
EV / revenue29.08
EV / EBITDA136.95
Gross margin100.00%
Operating margin74.37%
Profit margin29.40%
Return on equity10.98%
Return on assets4.55%
Debt / equity1.10
Current ratio21.71
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $46.02M | $434.43M | $60.00M | $26.58M | -89.4% |
| Operating revenue | $46.02M | $434.43M | $60.00M | $26.58M | -89.4% |
| Research & development | $159.29M | $138.13M | $120.16M | $126.22M | +15.3% |
| Selling, general & admin | $44.85M | $43.46M | $33.49M | $31.74M | +3.2% |
| Total operating expense | $204.14M | $181.59M | $153.65M | $157.95M | +12.4% |
| Operating income | -$158.13M | $252.84M | -$93.65M | -$131.37M | -162.5% |
| Net interest income | $28.79M | $26.32M | $14.90M | $4.06M | +9.4% |
| Pre-tax income | -$129.31M | $279.41M | -$78.95M | -$127.39M | -146.3% |
| Tax provision | $838.00K | $4.22M | $0 | $0 | -80.1% |
| Net income | -$130.15M | $275.19M | -$78.95M | -$127.39M | -147.3% |
| Net income to common | -$130.15M | $275.19M | -$78.95M | -$127.39M | -147.3% |
| Basic EPS | -2.05 | 4.47 | -1.39 | -2.60 | -145.9% |
| Diluted EPS | -2.05 | 4.23 | -1.39 | -2.60 | -148.5% |
| EBIT | -$158.13M | $252.84M | -$93.65M | -$131.37M | -162.5% |
| EBITDA | -$156.85M | $253.67M | -$92.67M | -$130.34M | -161.8% |
| Basic shares | 63.57M | 61.57M | 56.76M | 49.04M | +3.3% |
| Diluted shares | 63.57M | 65.08M | 56.76M | 49.04M | -2.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $128.39M | $97.25M | $186.73M | $125.74M | +32.0% |
| Cash & short-term investments | $567.36M | $418.91M | $341.62M | $237.35M | +35.4% |
| Total current assets | $577.57M | $591.64M | $355.58M | $243.08M | -2.4% |
| Property, plant & equipment | $11.69M | $12.61M | $2.15M | $4.63M | -7.3% |
| Total assets | $668.19M | $744.73M | $357.95M | $247.93M | -10.3% |
| Total current liabilities | $45.44M | $47.40M | $21.27M | $31.18M | -4.1% |
| Total debt | $10.32M | $10.87M | $1.14M | $3.66M | -5.0% |
| Total liabilities | $53.48M | $69.43M | $21.27M | $32.32M | -23.0% |
| Retained earnings | -$470.67M | -$340.52M | -$615.71M | -$536.75M | -38.2% |
| Shareholder equity | $614.71M | $675.29M | $336.68M | $215.61M | -9.0% |
| Working capital | $532.13M | $544.24M | $334.30M | $211.90M | -2.2% |
| Net tangible assets | $614.71M | $675.29M | $336.68M | $215.61M | -9.0% |
| Shares issued | 62.58M | 61.04M | 57.71M | 49.34M | +2.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$130.15M | $275.19M | -$78.95M | -$127.39M | -147.3% |
| Depreciation & amortisation | $1.28M | $826.00K | $977.00K | $1.03M | +55.0% |
| Stock-based compensation | $45.97M | $37.55M | $29.29M | $24.20M | +22.4% |
| Change in working capital | $146.21M | -$122.61M | -$19.51M | -$7.77M | +219.2% |
| Operating cash flow | $57.67M | $184.15M | -$70.24M | -$108.14M | -68.7% |
| Capital expenditure | -$1.59M | -$1.35M | -$609.00K | -$795.00K | -17.3% |
| Investing cash flow | -$49.33M | -$299.48M | -$39.26M | $91.47M | +83.5% |
| Financing cash flow | $22.86M | $25.85M | $170.48M | $18.84M | -11.6% |
| Free cash flow | $56.08M | $182.80M | -$70.84M | -$108.93M | -69.3% |
| End cash position | $128.68M | $97.47M | $186.95M | $125.97M | +32.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $213.47M | $56.37M | $7.44M | $4.71M | $5.55M | +278.7% |
| Operating revenue | $213.47M | $56.37M | $7.44M | $4.71M | $5.55M | +278.7% |
| Research & development | $42.06M | $46.74M | $46.36M | $40.00M | $37.04M | -10.0% |
| Selling, general & admin | $12.65M | $13.28M | $11.43M | $11.13M | $10.55M | -4.7% |
| Total operating expense | $54.71M | $60.02M | $57.79M | $51.13M | $47.59M | -8.8% |
| Operating income | $158.77M | -$3.65M | -$50.35M | -$46.42M | -$42.04M | +4,452.1% |
| Net interest income | $6.43M | $5.88M | $6.76M | $7.05M | $7.41M | +9.4% |
| Pre-tax income | $165.11M | $2.28M | -$43.72M | -$39.34M | -$34.60M | +7,138.7% |
| Tax provision | $2.27M | -$1.50M | $666.00K | $0 | $172.00K | +250.8% |
| Net income | $162.85M | $3.78M | -$44.38M | -$39.34M | -$34.77M | +4,204.8% |
| Net income to common | $162.85M | $3.78M | -$44.38M | -$39.34M | -$34.77M | +4,204.8% |
| Basic EPS | 2.47 | 0.06 | -0.69 | -0.62 | -0.55 | +4,016.7% |
| Diluted EPS | 2.29 | 0.05 | -0.69 | -0.62 | -0.55 | +4,480.0% |
| EBIT | $158.77M | -$3.65M | -$50.35M | -$46.42M | -$42.04M | +4,452.1% |
| EBITDA | $159.16M | -$3.24M | -$49.98M | -$46.06M | -$41.74M | +5,010.9% |
| Basic shares | 65.94M | 65.09M | 64.03M | 63.77M | 63.51M | +1.3% |
| Diluted shares | 71.01M | 70.49M | 64.03M | 63.77M | 63.51M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $420.08M | $193.71M | $128.39M | $113.71M | $168.54M | +116.9% |
| Cash & short-term investments | $782.58M | $547.79M | $567.36M | $576.12M | $570.47M | +42.9% |
| Total current assets | $807.15M | $613.46M | $577.57M | $586.42M | $602.53M | +31.6% |
| Property, plant & equipment | $10.40M | $11.17M | $11.69M | $12.27M | $12.70M | -6.9% |
| Total assets | $885.54M | $697.46M | $668.19M | $701.69M | $718.01M | +27.0% |
| Total current liabilities | $37.18M | $34.55M | $45.44M | $44.94M | $35.51M | +7.6% |
| Total debt | $9.22M | $9.78M | $10.32M | $10.75M | $11.28M | -5.7% |
| Total liabilities | $44.00M | $41.99M | $53.48M | $56.25M | $49.99M | +4.8% |
| Retained earnings | -$304.04M | -$466.89M | -$470.67M | -$426.29M | -$386.95M | +34.9% |
| Shareholder equity | $841.54M | $655.47M | $614.71M | $645.44M | $668.02M | +28.4% |
| Working capital | $769.97M | $578.91M | $532.13M | $541.48M | $567.02M | +33.0% |
| Net tangible assets | $841.54M | $655.47M | $614.71M | $645.44M | $668.02M | +28.4% |
| Shares issued | 64.67M | 64.23M | 62.58M | 62.45M | 62.11M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $162.85M | $3.78M | -$44.38M | -$39.34M | -$34.77M | +4,204.8% |
| Depreciation & amortisation | $397.00K | $407.00K | $376.00K | $361.00K | $304.00K | -2.5% |
| Stock-based compensation | $14.04M | $14.52M | $10.70M | $10.56M | $10.91M | -3.3% |
| Change in working capital | $42.37M | -$67.06M | -$2.67M | $28.06M | -$3.88M | +163.2% |
| Operating cash flow | $219.05M | -$48.94M | -$36.98M | -$1.94M | -$28.78M | +547.6% |
| Capital expenditure | -$168.00K | -$215.00K | -$144.00K | -$88.00K | -$813.00K | +21.9% |
| Investing cash flow | -$2.43M | $90.89M | $48.81M | -$58.55M | $54.81M | -102.7% |
| Financing cash flow | $9.74M | $23.37M | $2.84M | $5.66M | $2.92M | -58.3% |
| Free cash flow | $218.88M | -$49.16M | -$37.12M | -$2.02M | -$29.59M | +545.3% |
| End cash position | $420.37M | $194.00M | $128.68M | $114.00M | $168.83M | +116.7% |
Options analytics
Put / call volume
1.37
Put-heavy session
Put / call open interest
0.45
Positioning, not flow
Max pain
120.00
-13.5% from spot
ATM implied vol
54.7%
Nearest strike to spot
Skew (10% OTM)
+0.3%
Puts bid over calls
Call volume
71
Contracts, this expiry
Put volume
97
Contracts, this expiry
Heaviest call OI
150.00
137 contracts
Heaviest put OI
95.00
61 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.93 | 2.29 | +18.7% |
| Mar 2026 | -0.65 | 0.05 | +107.6% |
| Dec 2025 | -0.54 | -0.69 | -27.4% |
| Sep 2025 | -0.64 | -0.62 | +3.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.60 | 11 | $243.37M | +5,064.8% |
| Next quarter | -0.43 | 10 | $36.27M | +387.7% |
| Current year | 4.79 | 12 | $542.27M | +1,078.4% |
| Next year | -0.20 | 12 | $203.41M | -62.5% |
Analyst targets & ownership
Mean target$174.69
High target$225.00
Low target$149.00
Implied upside24.78%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy3 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders0.71%
Held by institutions119.66%
Institutions holding486
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
140.08
-0.05% from price
SMA 20
142.50
-2.67% from price
SMA 50
145.13
-4.44% from price
SMA 100
130.96
+6.90% from price
SMA 200
111.72
+24.14% from price
EMA 12
141.01
-0.72% from price
EMA 26
142.60
-1.82% from price
EMA 50
141.02
-0.72% from price
RSI (14)
41.6
Neutral
MACD (12,26,9)
-1.59
Hist -0.36
ATR (14)
4.71
3.40% of price
Realised vol 30D
26.7%
Annualised
Bollinger upper
148.34
20, 2σ
Bollinger lower
136.66
20, 2σ
50 / 200 cross
Golden
145.13 vs 111.72
Trend bias
Above 200
+24.14%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.20
Less volatile than market
Correlation to SPY
0.05
Largely independent
Realised vol 30D
26.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-16.4%
Peak to trough
Max drawdown 5Y
-81.0%
Peak to trough
ATR 14
4.71
3.40% of price
Beta (reported)
1.52
5Y monthly, from filing
Short interest
Shares short
8.14M
Prior 7.79M
Change vs prior
+4.5%
Shorts adding
% of float
14.62%
Elevated
% of shares out
12.58%
Against total outstanding
Days to cover
15.4
Crowded exit
Float
52.89M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 1, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Aug 31, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 31, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Aug 10, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 10, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 10, 26 | Goldman Sachs | UPGRADE | Neutral | Buy |
| Aug 6, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 14, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 7, 26 | Truist Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-8 POS · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-18
Periodic Financial Reports
10-Q · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-28
Offering Registrations
S-8 · 2026-02-25
Corporate Changes & Voting Matters
8-K · 2026-01-12
Periodic Financial Reports
10-Q · 2025-11-06
Periodic Financial Reports
10-Q · 2025-08-06
Headlines
The Peptide Boom That Isn’t About Your Muscles
The Wall Street Journal · 12d ago
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
GlobeNewswire · 15d ago
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
Zacks · 19d ago
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing
MT Newswires · 26d ago
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
ACCESS Newswire · 28d ago
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
Insider Monkey · 31d ago
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
Insider Monkey · 32d ago
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
ACCESS Newswire · 35d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.